Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are: How does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate ble
| Condition(s) | Peptic Ulcer Bleeding |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are: How does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate bleeding peptic ulcer patients in the Indonesian population? Researchers will compare the drug tegoprazan to lansoprazole with a double-blind randomized control to see their effect on healing bleeding peptic ulcers. Participants will: Take drug tegoprazan 50 mg OD or lansoprazole 30 mg OD every day for 2 weeks Endoscopic examination at the beginning before treatment and after completion of treatment within 2 weeks Record of their adverse effect occurrence |
| Who can participate | Inclusion Criteria: * Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination Exclusion Criteria: * Allergic to Tegoprazan or Lansoprazole * Diagnosed with gastric or duodenal cancer, pregnant * History of H. pylori infection treatment failure * Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis * Alcohol consumption * Undergoing chemotherapy |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Mario Steffanus |
| Locations | Jakarta, DKI Jakarta, Indonesia; Jakarta, DKI Jakarta, Indonesia |
| Start date | 2025-05-01 |
| NCT ID | NCT06894992 |
| Official listing | https://clinicaltrials.gov/study/NCT06894992 |